Data from the trial confirm that MINIject is a powerful treatment option to significantly reduce intraocular pressure (IOP), while decreasing the use of medication in patients with glaucoma 12 months post implant.
“This study demonstrates the remarkable potential efficacy of a stand-alone MIGS used ab interno in the supraciliary space,” stated glaucoma expert, Dr Steven Vold (Vold Vision, Fayetteville, AR), who will present the data at the AGS 2021 meeting. “The minimally invasive delivery of MIGS represents a safety advantage compared with other surgical treatments that require a bleb or that use an ab externo approach,” he explained.
The 2021 American Glaucoma Society Annual Meeting will be fully virtual, with live presentations taking place 4-7 March 2021. All meeting content will remain available to registered participants for six months after the meeting dates.